skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: High-dose radioiodine treatment for differentiated thyroid carcinoma is not associated with change in female fertility or any genetic risk to the offspring

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [1];  [1];  [1];  [1];  [1];  [2];  [2]
  1. Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi (India)
  2. Department of Biostatistics, All India Institute of Medical Sciences, New Delhi (India)

Background: We tried to evaluate the female fertility and genetic risk to the offspring from the exposure to high-dose {sup 131}I by assessing the pregnancy outcomes and health status of the children of female patients with differentiated thyroid cancer who had received therapeutic doses of {sup 131}I. Materials and Methods: From 1967 to 2002, a total of 1,282 women had been treated with {sup 131}I. Of these patients, 692 (54%) were in the reproductive age group (18-45 years). Forty women had a total of 50 pregnancies after high-dose {sup 131}I. Age at presentation ranged from 16 to 36 years (mean, 23 {+-} 4 years). Histopathology was papillary thyroid cancer in 32 cases and follicular thyroid cancer in 8 cases. Results: Single high-dose therapy was given in 30 cases, 2 doses were given in 7 cases, 3 doses were given in 2 cases, and four doses were given in 1 case in which lung metastases had occurred. In 37 patients (92%), disease was successfully ablated before pregnancy. Ovarian absorbed-radiation dose calculated by the MIRD method ranged from 3.5 to 60 cGy (mean, 12 {+-} 11 cGy). The interval between {sup 131}I therapy and pregnancy varied from 7 to 120 months (37.4 {+-} 28.2 months). Three spontaneous abortions occurred in 2 women. Forty-seven babies (20 females and 27 males) were born. Forty-four babies were healthy with normal birth weight and normal developmental milestones. Twenty women delivered their first baby after {sup 131}I therapy. The youngest child in our series is 11 months of age, and the oldest is 8.5 years of age. Conclusions: Female fertility is not affected by high-dose radioiodine treatment, and the therapy does not appear to be associated with any genetic risks to the offspring.

OSTI ID:
20702153
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 63, Issue 2; Other Information: DOI: 10.1016/j.ijrobp.2005.02.043; PII: S0360-3016(05)00404-9; Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

FETAL EFFECTS OF RADIOACTIVE IODINE THERAPY IN A PREGNANT WOMAN WITH THYROID CANCER
Journal Article · Mon May 01 00:00:00 EDT 1961 · American Journal of Obstetrics and Gynecology (U.S.) · OSTI ID:20702153

LATE RESULTS OF I$sup 131$ TREATMENT OF HYPERTHYROIDISM IN SEVENTY-THREE CHILDREN AND ADOLESCENTS
Journal Article · Sat Feb 01 00:00:00 EST 1964 · Journal of Nuclear Medicine (U.S.) · OSTI ID:20702153

Fertility and Pregnancy Outcome After Abdominal Irradiation That Included or Excluded the Pelvis in Childhood Tumor Survivors
Journal Article · Mon Mar 01 00:00:00 EST 2010 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20702153